VX-993
Sponsors
Vertex Pharmaceuticals Incorporated
Conditions
Acute PainDiabetic Peripheral Neuropathic PainPain
Phase 1
A Phase 1 Dose Escalation Study of VX-993 in Healthy Participants
CompletedNCT05653323
Start: 2022-12-14End: 2023-09-12Updated: 2023-10-12
A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993
CompletedNCT06226454
Start: 2024-01-04End: 2024-06-12Updated: 2024-07-12
A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy Adults
CompletedNCT06392659
Start: 2024-05-02End: 2024-07-02Updated: 2024-08-01
A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults
CompletedNCT06394167
Start: 2024-05-09End: 2025-02-18Updated: 2025-03-20
A Microneurography Study of NaV1.8 Inhibition in Healthy Adults
CompletedNCT06420765
Start: 2024-05-21End: 2025-04-04Updated: 2025-04-20
A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993
CompletedNCT06508762
Start: 2024-07-26End: 2024-09-10Updated: 2024-10-10
Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adults
CompletedNCT06523595
Start: 2024-07-31End: 2024-12-31Updated: 2025-01-31
Phase 2
A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy
CompletedNCT06619847
Start: 2024-10-29End: 2025-05-27Updated: 2025-06-26
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
RecruitingNCT06619860
Start: 2024-10-18End: 2026-05-30Target: 300Updated: 2026-03-16